AnaptysBio 2025 Q3 Earnings Record Revenue and 146% Net Income Surge

AnaptysBio (ANAB) delivered a dramatic turnaround in its fiscal 2025 Q3 earnings, reporting $76.32 million in revenue and $15.11 million in net income. The results far exceeded expectations, . CEO Daniel Faga outlined plans to separate biopharma and royalty assets by 2026 while highlighting Jemperli’s $785 million YTD sales and rosnilimab’s promising Phase 2b data.

Revenue

AnaptysBio’s total revenue soared to $76.32 million in Q3 2025, . This growth was driven entirely by collaboration revenue, . The year-over-year leap underscores the company’s ability to capitalize on milestone and royalty payments from partnerships, particularly with GSK’s Jemperli.

Earnings/Net Income

The company achieved a historic turnaround, , . Earnings per share (EPS) turned positive at $0.54, . This marks a significant milestone after 12 consecutive years of quarterly losses.

Price Action

AnaptysBio’s stock price experienced mixed post-earnings movement. , but gained 12.28% month-to-date. The volatility reflects investor skepticism amid a broader market rally, though the stock has surged 172.2% year-to-date, .

Post-Earnings Price Action Review

The stock’s immediate post-earnings reaction was tempered by short-term selling pressure, . However, the 12.28% monthly gain suggests underlying optimism about the company’s strategic shift and Jemperli’s commercial potential. Analysts remain cautious, , .

CEO Commentary

. , . , , were cited as key growth drivers.

Guidance

. . , .

Additional News

AnaptysBio announced plans to spin off its biopharma and royalty operations by 2026, aiming to streamline growth and enhance shareholder value. , . Additionally, , . .

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-qwen_generated_1762337621623.jpg.png" style="max-width:100%;">